| Cite this article: |
| ZHANG Cuipeng,YANG Yan,OU Beijin,PU Xueping,LIU Shikun,HU Keyu,ZHANG Youmei,LONG Yu.Exploring the value of combining PD-1 inhibitor immunotherapy with Lenvatinib targeted therapy for unresectable hepatocellular carcinoma[J].Journal Of Pharmaceutical Research,2025,44(7):725-728[Click to copy] |
|
| 摘要: |
| 目的 探讨PD-1抑制剂免疫治疗与靶向药物仑伐替尼联合治疗对不可切除肝细胞肝癌(uHCC)的疗效。方法 以我院及锦屏县人民医院2022年3月1日至2025年02月28日期间收治的50例不可切除肝细胞的肝癌患者为研究对象,采用简单随机对照,接受PD-1抑制剂与仑伐替尼免疫联合靶向治疗的25例患者纳入联合组;接受仑伐替尼单独治疗的25例患者纳入对照组。保持随访,使用mRECIST标准评价疗效,统计不良反应发生情况以及生存情况。结果 用药12个月后,两组中均无患者疗效达到CR;联合组ORR率、DCR率高于对照组(40.00%VS76.00%、12.00%VS44.00%,P<0.05)。PFS、OS中位时间联合组分别为9.5个月、18.9个月,对照组分别为5.4个月、11.2个月,以上指标组间数据比较差异有统计学意义(P<0.05)。3级及以上不良反应总发生率方面,联合组为28.00%,对照组为25.00%,两组比较差异无统计学意义(P>0.05)。结论 PD-1抑制剂免疫药物与仑伐替尼靶向药物的联合应用,在治疗无法手术切除的肝细胞癌方面,展现出在疗效和生存期延长上的明显优势,可为患者带来更好、更长的生存预期,不会明显增加患者不良反应发生风险,值得在符合条件的患者中推广使用。 |
| 关键词: PD-1抑制剂 仑伐替尼 肝细胞肝癌 |
| DOI:10.13506/j.cnki.jpr.2025.07.015 |
| 基金项目: |
|
|
|
| Exploring the value of combining PD-1 inhibitor immunotherapy with Lenvatinib targeted therapy for unresectable hepatocellular carcinoma |
| ZHANG Cuipeng,YANG Yan,OU Beijin,PU Xueping,LIU Shikun,HU Keyu,ZHANG Youmei,LONG Yu |
| (Department of Oncology, People's Hospital of Qiandongnan Miao and Dong Autonomous Prefecture,Kaili 556000,China) |
| Abstract: |
| Objective To investigate the efficacy of PD-1 inhibitor immunotherapy combined with targeted drug lenvatinib in the treatment of unresectable hepatocellular carcinoma (uHCC).Methods Fifty patients with unresectable hepatocellular carcinoma admitted to our hospital and Jinping County People's Hospital from March 1, 2022 to February 28, 2025 were selected as the study subjects. A simple randomized controlled trial was conducted, and 25 patients who received PD-1 inhibitor and Lenvatinib immunotherapy combined with targeted therapy were included in the combination group; 25 patients who received treatment with Lenvatinib alone were included in the control group. Maintain follow-up, evaluate efficacy using mRECIST criteria, and record the occurrence of adverse reactions and survival status.Results After 12 months of medication, no patients in both groups achieved complete response (CR);The ORR and DCR rates in the combination group were higher than those in the control group (40.00%VS76.00%, 12.00%VS44.00%, P<0.05). The median duration of PFS and OS in the combined group was 9.5 months and 18.9 months, respectively, while in the control group it was 5.4 months and 11.2 months, respectively. There was a statistically significant difference in the data comparison between the above indicators (P<0.05). In terms of the total incidence of grade 3 and above adverse reactions, the combination group was 28.00%, while the control group was 25.00%. There was no statistically significant difference between the two groups (P>0.05). Conclusion The combination of PD-1 inhibitor immunotherapy drugs and lenvatinib targeted drugs has shown significant advantages in efficacy and prolonged survival in the treatment of unresectable hepatocellular carcinoma. It can bring better and longer survival expectations to patients without significantly increasing the risk of adverse reactions, and is worth promoting in eligible patients. |
| Key words: PD-1 inhibitor Lenvatinib Unresectable hepatocellular carcinoma |